Ethosuximide
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Ethosuximide
- Ethosuximide: From Absence Seizures to Nephrogenic Syndrome of Inappropriate Antidiuresis
Ethosuximide: From Absence Seizures to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Ethosuximide is an anticonvulsant established for the treatment of absence seizures in epilepsy, acting via inhibition of thalamic T-type (Ca_v3) calcium channels. The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this prediction is currently supported by no clinical trials and no published literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Absence seizures (epilepsy) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Ethosuximide’s established mechanism of action is inhibition of T-type (Ca_v3) calcium channels in thalamic neurons, which reduces the abnormal neuronal firing underlying absence seizures. This is a well-characterised, neurone-specific electrophysiological effect.
NSIAD, in contrast, is caused by a gain-of-function mutation in the AVPR2 (vasopressin V2) receptor, which drives ADH-independent, constitutive activation of cAMP signalling and excessive water reabsorption in the renal collecting duct. This is a G-protein-coupled receptor/second-messenger pathway entirely distinct from voltage-gated neuronal calcium channels.
No known or indirect mechanistic link connects these two pathways, and no biological rationale currently supports repurposing ethosuximide for NSIAD. The high TxGNN score (99.91%) should therefore be interpreted as a knowledge-graph association rather than a pharmacologically validated hypothesis — it is not corroborated by any trial or literature evidence at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Ethosuximide currently holds no marketing authorisation on record and has a “not marketed” status; no UK product entries are available for this candidate indication.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial or literature evidence for this indication, and no established mechanistic link between ethosuximide’s known pharmacology and NSIAD pathophysiology. The evidence level (L5) reflects a model prediction only.
To proceed, the following is needed:
- Confirmed mechanism-of-action data for ethosuximide (currently a data gap)
- UK/MHRA product labelling, warnings and contraindications (currently a data gap)
- Preclinical or mechanistic studies exploring any plausible link between T-type calcium channel modulation and AVPR2/cAMP signalling
- At minimum, case reports or observational data before any further evaluation stage is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.